(GLOBE NEWSWIRE) — Las Vegas, Nevada, Jan. 12, 2022 (GLOBE NEWSWIRE) — DelveInsight examines the progress of the alcohol use disorder pipeline, which includes new and emerging drugs for treatment.
DelveInsight examines a robust Alcohol Use Disorder Pipeline that includes Adial Pharmaceuticals, MediciNova, Kinnov Therapeutics, Opiant Pharmaceuticals, Marperg, and a number of other firms active in the development of innovative 30+ Alcohol Use Disorder treatment regimens.
The 'Alcohol Use Disorder Pipeline Insight 2021' report from DelveInsight provides comprehensive global coverage of available, marketed, and pipeline therapies in various stages of clinical development, as well as major pharmaceutical companies working to advance the pipeline space and the domain's future growth potential. The following are some key points to remember from the Alcohol Use Disorder Pipeline report:
( https://www.digistore24.com/redir/382296/Ganga493/ )
DelveInsight's research of the Alcohol Use Disorder Pipeline shows a vibrant market with 30+ active firms working on 30+ pipeline therapy treatments.
Adial Pharmaceuticals, R-Pharm Synergy Research, Arbor Pharmaceuticals, Laboratorio Farmaceutico, Gilead Sciences, Kinnov Therapeutics, Opiant Pharmaceuticals, MediciNova, Bioprojet, Corcept Therapeutics, Pfizer, Dicerna Pharmaceuticals, Organon, Confluence Pharmaceuticals, Amygdala Neurosciences, Laboratorio Farmaceutico, Pfizer, Amygdala Neurosciences, Laboratori
WIL-1903, Nociceptin receptor agonists, CYB003, BXCL501, PT150, DCR-AUD, MAP4343, KT 110, Ibudilast/MN-166, AD04/Ondansetron, ANS-6637, GET73, and other essential alcohol use disorder pipeline medicines are in various stages of clinical studies.
Arbutus Biopharma is developing TKM-ALDH, a very unusual RNAi application. TKM-ALDH is intended to inhibit or silence the Aldehyde dehydrogenase (ALDH) enzyme, resulting in long-term acute sensitivity to ethanol, for use in the treatment of severe alcoholism. DCR-AUD is a GalXCTM RNAi investigational candidate from Dicerna that aims to silence ALDH2 (aldehyde dehydrogenase 2) mRNA expression in the liver. Phase I clinical trial to investigate DCR-AUD will begin in September 2021.
Adial Pharmaceuticals said in July 2020 that the European Medicines Agency (EMA) has approved its Pediatric Investigation Plan (PIP) for the development of AD04, the company's flagship medication candidate, for the treatment of alcohol use disorder (AUD) in children aged 12 to 17.
CTDP-002, orexin 1 antagonists, are being developed by Chronos Therapeutics to treat binge eating, alcoholism, and nicotine addiction.
Adial Pharmaceuticals has partnered with Tedor Pharma, a full-service contract development and manufacturing organization (CDMO), to deliver cGMP contract manufacturing services for AD04, a genetically targeted therapeutic agent for the treatment of Alcohol Use Disorder.
OPNT002 is a naltrexone intranasal formulation that acts quickly.
Phase I clinical data with OPNT002 demonstrated rapid intranasal absorption and a short duration of action compared to currently available products. Opiant plans to initiate a double-blind, placebo-controlled Phase II study in patients diagnosed with Alcohol Use Disorder.
Request a sample and discover more about the report offerings @ Alcohol Use Disorder Emerging Therapies
The Alcohol Use Disorder pipeline report lays down detailed profiles of the pipeline assets, comparative analysis of clinical and non-clinical stage Alcohol Use Disorder products, inactive and dormant assets, comprehensive assessment of driving and restraining factors, as well as the opportunities and risks in the Alcohol Use Disorder pipeline landscape.
Alcohol Use Disorder Overview
Alcohol Use Disorder also referred to as Alcoholism is the most severe form of alcohol abuse and involves the inability to manage drinking habits. It is also known as Alcohol Addiction. These are common and potentially lethal disorders that mimic and exacerbate a wide range of additional medical and psychiatric conditions, and thereby shorten the lifespans of affected people by more than a decade.
Find out more about the disease and recent developments @ Alcohol Use Disorder Pipeline Assessment
Alcohol Use Disorder Pipeline Drugs
Drug Company Phase MoA RoA WIL-1903 Whanin Pharmaceutical Preclinical NA Parenteral CYB003 Cybin Preclinical NA NA BXCL501 BioXcel Therapeutics Phase I Alpha 2 adrenergic receptor agonists Sublingual PT150 Pop Test Oncology Phase I Glucocorticoid receptor antagonists Oral DCR-AUD Dicerna Pharmaceuticals Phase I Aldehyde dehydrogenase 2 inhibitors Subcutaneous MAP4343 Mapreg Phase II Microtubule-associated protein stimulants Oral KT 110 Kinnov Therapeutics Phase II Alpha 1 adrenergic receptor antagonists Oral Ibudilast/MN-166 MediciNova Phase II Type 3, 4 cyclic nucleotide phosphodiesterase inhibitors Oral AD04/Ondansetron Adial Pharmaceuticals Phase III Serotonin 3 receptor antagonists Oral GET73 Laboratorio Farmaceutico Phase II Metabotropic glutamate receptor 5 antagonists Oral
Learn more about the novel and emerging Alcohol Use Disorder medications pipeline @ Alcohol Use Disorder Pipeline Analysis
Alcohol Use Disorder Therapeutics Assessment
The Alcohol Use Disorder Pipeline report proffers an integral view of the Alcohol Use Disorder emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.
By Alcohol Use Disorder Product Type
Mono
Combination
Mono/Combination
By Alcohol Use Disorder Clinical Stages
Discovery
Pre-clinical
Phase I
Phase II
Phase III
Pre-registration
By Alcohol Use Disorder Therapeutic Route of Administration
Oral
Intravenous
Inhalation
Subcutaneous
By Alcohol Use Disorder Therapies Molecule Type
Gene therapy
Stem cell therapy
Small molecules
By Alcohol Use Disorder Therapies Mechanism of Action
Metabotropic glutamate receptor 5 antagonists
Serotonin 3 receptor antagonists
Alpha 1 adrenergic receptor antagonists
Aldehyde dehydrogenase 2 inhibitor
Glucocorticoid receptor antagonists
Opioid receptor antagonists
Microtubule-associated protein stimulants
Scope of the Alcohol Use Disorder Pipeline Report
Coverage: Global
Major Alcohol Use Disorder Players: Adial Pharmaceuticals, R-Pharm Synergy Research, Arbor Pharmaceuticals, Laboratorio Farmaceutico, Gilead Sciences, Kinnov Therapeutics, Opiant Pharmaceuticals, MediciNova, Bioprojet, Corcept Therapeutics, Pfizer, Dicerna Pharmaceuticals, Organon, Confluence Pharmaceuticals, Amygdala Neurosciences, Laboratorio Farmaceutico, Pop Test Oncology, Whanin Pharmaceutical, Astraea Therapeutics, Cybin, BioXcel Therapeutics, Mapreg, Arbutus Biopharma
Key Alcohol Use Disorder Pipeline Therapies: WIL-1903, Nociceptin receptor agonists, CYB003, BXCL501, PT150, DCR-AUD, MAP4343, KT 110, Ibudilast/MN-166, AD04/Ondansetron, ANS-6637, GET73
Dive deep into rich insights about emerging drugs for Alcohol Use Disorder assessment, visit @ Alcohol Use Disorder Emerging Therapies
Table of Contents
1 Introduction 2 Executive Summary 3 Alcohol Use Disorder: Overview 4 Alcohol Use Disorder Pipeline Therapeutics 5 Alcohol Use Disorder: Late Stage Products (Phase III) 5.1 AD04: Adial Pharmaceuticals 6 Alcohol Use Disorder: Mid Stage Products (Phase II) 6.1 KT 110: Kinnov Therapeutics 7 Alcohol Use Disorder: Mid Stage Products (Phase II) 7.1 Ibudilast: MediciNova 8 Alcohol Use Disorder: Early Stage Products (Phase I) 8.1 PT150: Pop Test Oncology 9 Alcohol Use Disorder: Early Stage Products (Phase I) 9.1 BXCL501: BioXcel Therapeutics 10 Alcohol Use Disorder: Preclinical Stage Products 11 Alcohol Use Disorder Therapeutic Assessment 12 Inactive Products in Alcohol Use Disorder 13 Collaborations Assessment- Licensing / Partnering / Funding 14 Alcohol Use Disorder- Unmet Needs 15 Alcohol Use Disorder- Market Drivers and Barriers 16 Appendix 17 About DelveInsight
For further information on the Alcohol Use Disorder current pipeline therapeutics, reach out @ Alcohol Use Disorder Ongoing Clinical Trials
Track and assess a candidate's clinical development journey through Actionable Intelligence and Comparative Therapeutic Assessment
Related Reports
Alcohol Use Disorder Market
DelveInsight's ‘Alcohol Use Disorder Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, market trends, market drivers, market barriers, and key companies involved such as Merck Sante, Odyssey pharmaceuticals, Dupont, MediciNova, Adial Pharmaceuticals, Tonix Pharmaceuticals, and others.
Alcohol Use Disorder Epidemiology
DelveInsight's ‘Alcohol Use Disorder- Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical, and forecasted Alcohol Use Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Alcoholic Hepatitis Market
DelveInsight's ‘Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast – 2030' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends, market drivers, market barriers, and key companies involved such as DURECT Corporation, Novartis, and many others.
Alcoholic Hepatitis Pipeline
DelveInsight's, "Alcoholic Hepatitis – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Alcoholic Hepatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, and key companies involved such as Durect, Novartis, Immuron Ltd, Immunemed, Evive Biotech, Surrozen, Arrowhead Pharmaceuticals, Seal rock therapeutics, and many others.
Smoking Cessation Market
DelveInsight's ‘Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030' report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends, market drivers, market barriers, unmet medical needs, SWOT analysis and key companies involved such as Pfizer, GlaxoSmithKline, Axsome Therapeutics, Achieve Life Sciences, Chronic Airway Therapeutics, Smoke Free Therapeutics (NFL Biosciences SAS), Novo Nordisk, and many others.
Smoking Cessation and Nicotine Deaddiction Pipeline
DelveInsight's, "Smoking Cessation and Nicotine Deaddiction – Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key companies involved such as Achieve LifeSciences, NFL Biosciences, Axsome Therapeutics, and others.
Cocaine Use Disorder Pipeline
DelveInsight's, "Cocaine Use Disorder - Pipeline Insight, 2021," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Cocaine Use Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products and key companies involved such as Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics, and others.
7 Days to Drink Less Online Alcohol Reduction Program ;
( https://www.digistore24.com/redir/382296/Ganga493/ )